HomeComparePPAAF vs MRK

PPAAF vs MRK: Dividend Comparison 2026

PPAAF yields 7.69% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PPAAF wins by $80200.16M in total portfolio value
10 years
PPAAF
PPAAF
● Live price
7.69%
Share price
$0.13
Annual div
$0.01
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80200.22M
Annual income
$78,246,133,996.48
Full PPAAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — PPAAF vs MRK

📍 PPAAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPAAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPAAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPAAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPAAF
Annual income on $10K today (after 15% tax)
$653.85/yr
After 10yr DRIP, annual income (after tax)
$66,509,213,897.01/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, PPAAF beats the other by $66,509,205,300.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPAAF + MRK for your $10,000?

PPAAF: 50%MRK: 50%
100% MRK50/50100% PPAAF
Portfolio after 10yr
$40100.14M
Annual income
$39,123,072,055.13/yr
Blended yield
97.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PPAAF
No analyst data
Altman Z
1.8
Piotroski
8/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPAAF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPAAFMRK
Forward yield7.69%2.81%
Annual dividend / share$0.01$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$80200.22M$57.7K
Annual income after 10y$78,246,133,996.48$10,113.78
Total dividends collected$80066.57M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PPAAF vs MRK ($10,000, DRIP)

YearPPAAF PortfolioPPAAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,238$1,538.46$11,213$373.04+$1.0KPPAAF
2$16,614$3,519.33$12,667$512.06+$3.9KPPAAF
3$26,708$8,930.30$14,439$708.14+$12.3KPPAAF
4$55,410$26,832.63$16,640$988.16+$38.8KPPAAF
5$163,343$104,054.15$19,432$1,394.07+$143.9KPPAAF
6$748,124$573,347.31$23,057$1,992.90+$725.1KPPAAF
7$5,708,866$4,908,373.63$27,889$2,894.79+$5.68MPPAAF
8$76,118,483$70,009,996.01$34,518$4,286.29+$76.08MPPAAF
9$1,826,250,231$1,744,803,453.99$43,912$6,494.35+$1826.21MPPAAF
10$80,200,221,744$78,246,133,996.48$57,714$10,113.78+$80200.16MPPAAF

PPAAF vs MRK: Complete Analysis 2026

PPAAFStock

PT Perusahaan Gas Negara Tbk, together with its subsidiaries, engages in the transmission and distribution of natural gas to industrial, commercial, and household users in Indonesia and the United States. It operates through three segments: Gas commercial and transmission, Exploration and Production of Oil and Gas, and Other operations. It is also involved in the liquefied natural gas processing activity; trading of oil and gas; and exploration, exploitation, and business development in oil and gas. In addition, the company provides fiber optic rental for network services; construction and maintenance services to the customers; management and leasing services for buildings and equipment; and engineering and consultancy services. The company was founded in 1859 and is headquartered in Jakarta, Indonesia. PT Perusahaan Gas Negara Tbk is a subsidiary of PT Pertamina (Persero).

Full PPAAF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PPAAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPAAF vs SCHDPPAAF vs JEPIPPAAF vs OPPAAF vs KOPPAAF vs MAINPPAAF vs JNJPPAAF vs ABBVPPAAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.